- Home
- EVAX vs GYRO Comparison
EVAX vs GYRO Comparison
Compare EVAX & GYRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- GYRO
- Stock Information
- Founded
- EVAX 2008
- GYRO 1946
- Country
- EVAX Denmark
- GYRO United States
- Employees
- EVAX N/A
- GYRO N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- GYRO Building operators
- Sector
- EVAX Health Care
- GYRO Real Estate
- Exchange
- EVAX Nasdaq
- GYRO Nasdaq
- Market Cap
- EVAX 16.3M
- GYRO 19.3M
- IPO Year
- EVAX 2021
- GYRO N/A
- Fundamental
- Price
- EVAX $1.69
- GYRO $8.10
- Analyst Decision
- EVAX Strong Buy
- GYRO
- Analyst Count
- EVAX 2
- GYRO 0
- Target Price
- EVAX $10.00
- GYRO N/A
- AVG Volume (30 Days)
- EVAX 65.8K
- GYRO 818.0
- Earning Date
- EVAX 05-27-2025
- GYRO 01-01-0001
- Dividend Yield
- EVAX N/A
- GYRO N/A
- EPS Growth
- EVAX N/A
- GYRO N/A
- EPS
- EVAX N/A
- GYRO N/A
- Revenue
- EVAX $3,344,000.00
- GYRO $2,738,019.00
- Revenue This Year
- EVAX $102.45
- GYRO N/A
- Revenue Next Year
- EVAX $200.44
- GYRO N/A
- P/E Ratio
- EVAX N/A
- GYRO N/A
- Revenue Growth
- EVAX 4480.82
- GYRO N/A
- 52 Week Low
- EVAX $1.61
- GYRO $7.65
- 52 Week High
- EVAX $22.05
- GYRO $11.96
- Technical
- Relative Strength Index (RSI)
- EVAX 36.47
- GYRO 24.74
- Support Level
- EVAX $1.67
- GYRO $8.13
- Resistance Level
- EVAX $1.97
- GYRO $8.55
- Average True Range (ATR)
- EVAX 0.12
- GYRO 0.11
- MACD
- EVAX 0.04
- GYRO -0.00
- Stochastic Oscillator
- EVAX 22.22
- GYRO 0.00
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About GYRO Gyrodyne LLC
Gyrodyne LLC is a United States-based limited liability company. It operates in the ownership and management of industrial and medical office buildings segment. The company leases and manages various commercial properties such as medical offices and industrial properties. The properties owned by the company include Cortlandt Manor and Flowerfield.